Form 4: CalciMedica Chief Scientific Officer Acquires Stock Options
SEC Form 4 Filing
Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., acquired employee stock options on March 28, 2024.
Summary
- Kenneth A. Stauderman, the Chief Scientific Officer of CalciMedica, Inc., acquired 62,500 employee stock options on March 28, 2024.
- The exercise price of these options is $4.16.
- The options vest in equal monthly installments over a four-year period following the grant date.
- The options expire on March 27, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a company insider's acquisition of stock options, a common form of executive compensation.
Stakeholder Impact
- The acquisition of stock options by a key executive could potentially align management's interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/28/2024 | Date of transaction: Kenneth A. Stauderman acquired employee stock options. |
| 03/27/2034 | Expiration date of the employee stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.